Hims & Hers Health Enters Menopause Market in $1B Revenue Push

Hims & Hers Health has announced the expansion of its virtual care platform to include comprehensive menopause and perimenopause services, marking a significant step in its bid to exceed $1 billion in annual revenue by 2026. Following the announcement, company shares rose approximately 18% on Wednesday.

The digital health company, which currently serves more than 500,000 subscribers, is targeting a long-underserved segment of women’s health. Each year, an estimated 1.3 million women in the United States enter menopause, yet only 30% of OB/GYNs receive formal training in menopause management. This shortage contributes to widespread under-treatment of symptoms such as hot flashes, mood shifts, sleep disturbances, and skin and hair changes.

Through the Hers platform, patients will have access to licensed providers specializing in menopause and perimenopause care. Treatment plans may include hormone therapies—such as estradiol in pill, patch, or cream forms—and progesterone, as well as non-hormonal options tailored to individual health profiles and preferences. Patients can collaborate with their providers to modify treatment as needed.

“This isn’t just about medication—it’s about building and growing a platform that women can trust to access the care they need,” said Jessica Shepherd, MD, Chief Medical Officer of Hers. “Women have been navigating an outdated healthcare system that wasn’t designed for them for too long.”

Hims & Hers plans to expand its menopause and perimenopause offerings further in 2026. The move comes as competition in the virtual menopause care market intensifies. Midi Health, which raised $60 million in April 2024, is scaling its telehealth model and expanding insurance coverage nationwide. Other notable players include MyMenopauseRx, Evernow, and Carrot Fertility, which recently launched a menopause clinic for employer clients.

This expansion follows Hims & Hers’ recent entry into testosterone therapy and reflects a broader strategic pivot away from compounded weight-loss drugs amid increased regulatory oversight. The company’s latest initiative underscores its ambition to become a leading destination for comprehensive, gender-specific virtual healthcare.

Click here for the original news story.